Skip to main content
Fig. 3 | Retrovirology

Fig. 3

From: HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial

Fig. 3

Anti-Tat Ab durability in responders. a Kaplan–Meier estimates showing the cumulative probability of anti-Tat Ab durability during follow-up in responders (see “Methods” section) (vaccinees: n = 96; placebos: n = 18). Anti-Tat Abs persisted significantly longer in vaccinees as compared to the placebo group (p = 0.0019, log-rank test). b Kaplan–Meier estimates showing the cumulative probability of anti-Tat Ab durability during follow-up in vaccinees (left panel) or placebo (right panel) responders, according to the number of anti-Tat Ab isotypes (vaccinees: one subclass n = 10, two or three subclasses n = 86; placebo: one subclass n = 10, two or three subclasses n = 8)

Back to article page

Retrovirology

ISSN: 1742-4690

Contact us